Chemotherapy for stomach cancer with blocked intestines
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial tests a chemotherapy combination (docetaxel, oxaliplatin, and 5-FU) in people with stomach or gastroesophageal cancer that has spread to the lining of the abdomen and is causing an inoperable bowel blockage. It aims to shrink or control the blockage and cancer when surgery cannot be done.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your stomach or lower esophagus cancer has been confirmed as adenocarcinoma by pathology.
- Your cancer has spread in the abdomen lining (peritoneal carcinomatosis) based on scans or tissue testing.
- You have a bowel blockage below the Treitz ligament that cannot be fixed with surgery, confirmed by two surgeons.
- Your body and organs meet basic lab limits (enough blood counts, and kidney/liver tests are not too high).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding the chemotherapy drug paclitaxel directly into the abdomen (intraperitoneal) along with standard IV chemotherapy for people with stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen. The goal is to see if this combination helps control the cancer better than standard treatment alone.
This Phase 2 study tests a combination chemotherapy regimen given before surgery for stomach cancer that cannot be fully removed (unresectable), including spread to lymph nodes. The goal is to shrink the cancer and improve control with a well-known set of medicines given in a specific order.
This trial tests a combination chemotherapy plan—paclitaxel (albumin-bound), oxaliplatin, and S-1 given before surgery—to try to shrink stomach cancer and improve the chance of successful tumor removal. It is for people whose cancer is locally advanced or has spread, but might still be resectable (removable) in certain cases.
This trial tests a new immunotherapy drug (SHR-1701) combined with chemotherapy for people with stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen (peritoneal metastasis) but not to other organs like the liver or lungs. The goal is to see if this combination can help shrink or control the cancer before any surgery.
This Phase 1 trial tests how well a tailored (response-adapted) chemotherapy plan works before surgery for stomach or gastroesophageal junction cancer. It aims to improve treatment planning while checking early safety.
This trial tests if surgery to remove visible cancer in the belly combined with heated chemotherapy placed directly into the abdomen can help people with stomach cancer that has spread to the lining of the belly. It is for patients who are well enough to undergo major surgery and meet specific health requirements.
Hear when a new Metastatic Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.